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 Conclusions :  The TEG ® 6s system can improve diagnostic accuracy 
with a high degree of correlation to the Clauss assay. By using com-
plementary data from CFF.MA (particularly above the RR for the 
other assays) and CK.MA a more complete assessment of hemostasis 
can be obtained. 
 
 PB0151  |  The New QXpert Analyser Is Suitable 
for Routine Use in High Volume Haemostasis 
Laboratories 
 A.  Woolley ;  M.  Bryant ;  L.  Marley ;  S.  Kitchen 
 Sheffield Haemophilia and Thrombosis Centre, Coagulation Department, 
Sheffield, United Kingdom 
 Background :  The QXpert ( Grifols) is a recently launched fully auto-
mated, random access, cap piercing analyser using clotting, chromo-
genic and immunoturbidometric methods suitable for high volume 
laboratories. Liquid PT/INR (recombinant human tissue factor), 
APTT (ellagic acid/synthetic phospholipids) and fibrinogen (human 
thrombin) reagents are available for ease of use. 
 Aims :  We have evaluated the QXpert for routine use in comparison 
to a widely used alternative system as recommended by CLSI. 
 Methods :  We compared QXpert with CS5100 (Sysmex) with the fol-
lowing: PT/INR; liquid human recombinant thromboplastin (DG- PT 
RecombiLIQ) vs Innovin (Siemens): APTT; liquid ellagic acid APTT 
(DG- APTT Synth) vs Actin FS: Fibrinogen; liquid human thrombin re-
agent (DG- FIB L Human) vs Siemens Thrombin: Ddimer; Latex assay 
(Grifols) vs Innovance. The following groups were studied: normal 
subjects (n= 21- 53); warfarinised patients (n = 134); subjects with 
congenital deficiency states (n= 43 intrinsic defects): acquired co-
agulation disorders such as liver disease/DIC/critical care (n= 33). 
 Results :  Table 1 shows mean INRs results. There was no significant 
difference between INRs with the two systems for subjects with 
INRs < 4 when all data were combined. Differences observed at 
higher INRs were unlikely to be clinically relevant. Of 23 cases with 
isolated FVIII or FIX deficiency (including 11 with FVIII or FIX be-
tween 0.30 and 0.56 IU/ml) only 1 case (FIX 0.41 IU/ml) had a normal 
APTT with DG- APTT Synth. There was no significant difference and 
a good correlation between fibrinogen results and between DDimer 
results by the 2 methods in normal subjects/Liver disease/DIC. 
 Conclusions :  Sensitivity to deficiency of FVIII and FIX was excellent 
and INRs were in acceptable agreement with a widely used method. 
The QXpert is suitable for routine use in high throughput labora-
tories in combination with liquid reagents from Diagnostic Grifols. 
 PB0152  |  Assessment of the Efficacy and the 
Impact of the Rapid, Practical and Ergonomic 
DOAC & Platelets Filter Device on Thrombin 
Generation Assay 
 D.  Gheldof 1  ;  A.-S.  Delvigne 1  ;  C.  Bouvy 2  ;  J.  Douxfils 1,2  ;  J.-M. 
 Dogné 1  
 1 University of Namur, Namur, Belgium,  2 Qualiblood s.a., Namur, Belgium 
 Background :  Thrombin generation assay (TGA) is known to be highly 
sensitive to direct oral anticoagulants (DOACs). It provides more in-
formation thank to its capacity to explore in more details the kinetic 
formation of thrombin. Devices with adsorbent properties that are 
used to remove DOACs from plasma samples are usually known to 
interfere with TGA parameters at normal tissue factor (TF) concen-
tration (i.e. 5 pM of TF) by increasing the peak, the mVRI and by 
reducing the time- to- peak. This prevents the use a ratio of the condi-
tions before/after removal of DOAC to assess the intensity of anti-
coagulation at the individual patients’ level. 
 Aims :  To assess the efficacy and the impact of the DOAC & Platelets 
Filter (DP- Filter) device from the University of Namur on TGA pa-
rameters from plasma spiked with DOACs. 
 Methods :  Normal pooled plasma (NPP) was mixed with apixaban, 
betrixaban, dabigatran, edoxaban or rivaroxaban at concentrations 
of 0- 100- 300- 1000 ng/ml. Plasma were tested before and after fil-
tration on the calibrated automated thrombogram using the PPP- 
high reagent (20 pM of TF). 
 Results :  All DOACs affect TGA parameters. Filtration with DP- Filter 
efficiently restores baseline value of the lag time at 105±9% and the 
ETP at 93±9% for all DOACs whatever the concentration. The peak 
parameters are restored with DP- Filter at 98±7% for edoxaban, ri-
varoxaban and betrixaban. However, it seems that the device is not 
 TA B L E  1  INRs with DG- PT RecombiLIQ and Innovin
 Group  n 
 Mean INR 
- RecombiLIQ/QXpert  Mean INR Innovin/CS5100 
 Difference 
(RecombiLIQ- Innovin 
 Significance Paired 
t test 
 INRs <2.0  21  1.65  1.62  2%  ns(p=0.77) 
 INRs 2- 2.4  20  2.24  2.23  <1%  ns(0.87) 
 INRs 2.5- 2.9  22  2.71  2.80  - 3%  ns(0.17) 
 INRs 3.0- 3.4  28  3.19  3.42  - 7%  p<0.0001 
 INRs 3.5- 4.0  20  3.69  4.15  - 12%  p<0.0001 
 All INRs <4.0  111  2.72  2.87  - 5%  ns(p=0.16) 
 INRs >4.0  23  4.69  5.80  - 19%  p=0.01 
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able to totally restore initial peak in plasma samples spiked with 
apixaban and dabigatran (75±20% and 83±7%, respectively). 
 Conclusions :  DP- filter device is effective in removing DOACs from 
plasma. It allows to recover the baseline TGA profile of the NPP. The 
use a ratio of the conditions before/after removal of DOAC appears 
to be feasible using reagents with high TF content. It could provide 
interesting information on the level of anticoagulation at the indi-
vidual patient ' s level. 
 PB0153  |  Thromboelastography Cartridge- 
based System Measurements Reflect Both 
Platelet Count and Function Contribution to Clot 
Formation: An Ex- vivo Evaluation 
 J.D.  Dias 1  ;  C.G.  Lopez-Espina 2  ;  J.  Hartmann 3  ;  H.E.  Achneck 3  
 1 Haemonetics Corporation, Signy, Switzerland,  2 Haemonetics Corporation, 
Rosemont, IL, United States,  3 Haemonetics Corporation, Braintree, MA, United 
States 
 Background :  Low platelet count remains the trigger for platelet 
transfusion in multiple guidelines; however, there is an increasing 
body of evidence supporting a more comprehensive assessment of 
coagulation. Studies have shown that using thromboelastography 
to guide transfusion can improve outcomes compared with conven-
tional coagulation assay protocols. 
 Aims :  To determine if the new cartridge- based TEG ® 6s can accu-
rately evaluate the contributions of both platelet count and platelet 
function (aggregation) to maximum clot strength. 
 Methods :  TEG ® 6s assays were performed on whole blood samples 
from eight healthy volunteers to determine platelet count (n=5) and 
platelet function (n=5). Maximum amplitude (MA) was assessed 
for functional fibrinogen (CFF), RapidTEG ®  (CRT), Kaolin (CK) and 
Kaolin with heparinase (CKH). Platelet count was measured using 
complete blood count. Abciximab was used to inhibit platelet ag-
gregation, and platelet function was evaluated by light transmission 
aggregometry (LTA) with TRAP agonist. The relationship between 
TEG ® 6s parameters and platelet count values or concentration lev-
els of abciximab was studied in the framework of generalized linear 
or nonlinear models. 
 Results :  There was a positive correlation between platelet count and 
CK.MA, CRT.MA and CKH.MA (p< 0.0001). Abciximab concentra-
tion displayed an inverse relationship with CK.MA, CRT.MA, and 
CKH.MA (p< 0.001); no significant relationship was observed with 
CFF.MA (p=0.24). Platelet count reduction effects could be meas-
ured for concentrations < 92 platelets/μL for CK.MA, < 74 platelets/
μL for CRT.MA, and < 87 platelets/μL for CKH.MA. Furthermore, 
platelet function inhibition could be detected by all three assays at 
levels >66% as measured by LTA. 
 Conclusions :  These results demonstrate that the TEG ® 6s system 
can be used to accurately evaluate platelet count and function at 
the point of care, providing a comprehensive overview of platelet 
contribution to coagulation. Further trials are needed to elucidate 
the clinical benefit of TEG ® 6s guided platelet transfusions versus 
platelet count alone. 
 PB0155  |  Inter- reagents Agreement of D- dimer 
Test Results in the Low Range of Concentrations 
 P.  Toulon 1  ;  M.  Smahi 2  ;  N.  De Pooter 3  
 1 Pasteur University Hospital, Hematology, Nice, France,  2 Simone Veil Hospital, 
Hematology, Eaubonne, France,  3 Grasse General Hospital, Hematology, Grasse, 
France 
 Background :  Main indications for D- dimer testing include diagno-
sis of DIC and exclusion of VTE diagnosis. Recently, D- dimer was 
found valuable in guiding the duration of anticoagulation after a 
thrombotic event. In that respect, the “HERDOO2” clinical deci-
sion rule to guide duration of anticoagulation in women with unpro-
voked VTE includes  H yperpigmentation,  E dema,  R edness of lower 
extremity, Vidas  D - Dimer≥250 ng/mL,  O besity, and  O lder age≥65 
years. 
 Aims :  As D- dimer assays are not standardized, the aim of the present 
study was to evaluate the inter- reagent agreement of results in the 
low range of concentrations. 
 Methods :  For that purpose, we investigated plasma samples 
from 50 patients (31 males and 30 females, mean age=34 years, 
range:18- 72) in whom D- dimer testing was prescribed for VTE ex-
clusion. D- dimer was evaluated using 4 different quantitative auto-
mated latex agglutination- based assays: HemosIL D- dimer HS500 
(Werfen),HemosIL Accustar D- dimer (Werfen),Innovance D- dimer 
(Siemens),STA- Liatest D- dimer (Stago), and with the Vidas D- dimer 
Exclusion II (BioMérieux). 
 Results :  Test results (Table) were well correlated with those ob-
tained with the Vidas (r 2 >0.40, except for one reagent). 
 The concordance of test results below or above the cut- off level 
of 250 ng/mL (270 for Liatest, as its limit of quantitation) assessed 
 TA B L E  1
 
 HemosIL D- dimer 
HS500 
 HemosIL AcuStar 
D- dimer  Innovance D- dimer  STA- Liatest D- dimer 
 Vidas D- dimer 
Exclusion II 
 D- dimer (ng/mL FEU) 
Median (range) 
 224 (<203 - 402)  209 (83 - 570)  345 (<170 - 630)  300 (<270 - 710)  244 ( 121 - 536) 
 r2 (with Vidas)   0.403  0.417  0.201  0.483  - 
 Concordance with 
Vidas <250 ng/mL 
 Kappa=0.608  Kappa=0.448  Kappa=0.295  Kappa=0.608 (using 
270 ng/mL) 
 - 
